INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES
[ISSN: 0975-4725; CODEN(USA): IJPS00]
Journal Homepage: https://www.ijpsjournal.com

Review Article

Therapeutic Approaches to Type 2 Diabetes Remission: Challenges, Lifestyle Modifications, and Genetic Innovations

Sohel Tamboli*, Madhura Mundhe, Suraj Nanaware

Department of Pharmacology, SBNM College of Pharmacy, Alni, Dharashiv, Maharashtra, India 413501

ARTICLE INFO

Published: 13 Aug 2026
Keywords:
Type 2 diabetes remission, Twin Cycle Hypothesis, Bariatric surgery, Lifestyle modification, SGLT2 inhibitors, GLP-1 receptor agonists
DOI:
10.5281/zenodo.21927152

ABSTRACT

Type 2 diabetes mellitus (T2DM) has traditionally been managed as a chronic, progressive disease, but accumulating clinical evidence indicates that sustained remission is achievable in a substantial subset of patients. This review synthesizes 38 peer-reviewed studies published up to December 2024, covering six intervention domains: dietary modification, weight management, bariatric surgery, pharmacotherapy (SGLT2 inhibitors and GLP-1 receptor agonists), intermittent fasting, and regenerative/genetic approaches, with evidence quality assessed using a GRADE-informed framework. Ectopic fat accumulation in the liver and pancreas - the Twin Cycle Hypothesis - emerged as the central, reversible mechanism underlying T2DM. Bariatric surgery and intensive caloric restriction provided the strongest and most durable evidence for remission, with remission rates of 30-60% at five to ten years post-surgery, and approximately 46% and 36% at 12 and 24 months, respectively, following the DiRECT dietary protocol. SGLT2 inhibitors and GLP-1 receptor agonists offered substantial cardiorenal and metabolic benefit without, in isolation, producing complete remission. Stem cell and CRISPR-based interventions remain preclinical or early-phase, with evidence graded as very low. T2DM should be reconceptualized as a metabolically reversible disease in many patients when intervention targets ectopic fat accumulation directly; a precision-medicine framework integrating disease duration, residual beta-cell function, adiposity, and psychosocial context is proposed to guide selection of remission-oriented therapy.

INTRODUCTION

Diabetes mellitus is a complex metabolic disorder characterized by chronic hyperglycemia resulting from impaired insulin secretion, insufficient insulin action, or both, producing widespread disturbances in carbohydrate, lipid, and protein metabolism[1]. The global prevalence of type 2 diabetes mellitus (T2DM) has risen sharply in recent decades, driven by urbanization, sedentary

***Corresponding Author:** Sohel Tamboli
Address: *Department of Pharmacology, SBNM College of Pharmacy, Alni, Dharashiv, Maharashtra, India 413501.*
Email : drsoheltamboli@gmail.com
Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

lifestyles, dietary transition, and population aging[2]. T2DM accounts for more than 90% of all diabetes cases and is closely associated with obesity, insulin resistance, and polygenic susceptibility[3].

Persistent hyperglycemia contributes to microvascular complications - retinopathy, nephropathy, and peripheral neuropathy - as well as macrovascular disease, including coronary artery disease, cerebrovascular disease, and peripheral arterial disease[4]. Despite advances in pharmacotherapy and glucose monitoring, diabetes-related morbidity and mortality remain high, underscoring the limitations of conventional stepwise management[5].

T2DM has historically been framed as progressive and irreversible, with care centered on stepwise pharmacological escalation. This approach does not directly address the underlying drivers of disease progression - insulin resistance, ectopic fat accumulation, and beta-cell dysfunction[6,7] - and many patients experience progressive deterioration in glycemic control, ultimately requiring insulin therapy[8].

This paradigm is now being reconsidered. Emerging evidence demonstrates that T2DM is, in many individuals, a reversible metabolic condition when interventions target root-cause mechanisms rather than hyperglycemia alone[6,8]. Sustained normoglycemia without glucose-lowering pharmacotherapy - diabetes remission - has been documented following intensive lifestyle modification, substantial weight loss, bariatric surgery, and selected pharmacological interventions[8]. This review synthesizes the evidence base for T2DM remission across lifestyle, pharmacological, surgical, cellular, and genetic modalities, and proposes a precision-medicine framework for remission-oriented clinical practice.

MATERIALS AND METHODS

This review was conducted in accordance with PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) 2020 guidelines. PubMed/MEDLINE, EMBASE, Cochrane Library, and Google Scholar were searched up to December 2024 using the terms: type 2 diabetes mellitus, diabetes remission, diabetes reversal, glycemic control, lifestyle modification, bariatric surgery, SGLT2 inhibitors, GLP-1 receptor agonists, stem cell therapy, gene therapy, CRISPR-Cas9, and Twin Cycle Hypothesis.

Studies were included if they reported outcomes related to glycemic control (HbA1c, fasting plasma glucose, or C-peptide levels); evaluated lifestyle, pharmacological, surgical, cellular, or genetic interventions relevant to T2DM remission; enrolled adults (≥ 18 years) with confirmed T2DM; and provided quantitative or mechanistic outcomes relevant to remission or sustained metabolic health. Remission was defined per the American Diabetes Association consensus[9] as HbA1c <6.5% sustained for at least three months without glucose-lowering pharmacotherapy. Studies were excluded if they focused exclusively on pediatric populations, investigated non-diabetic conditions, were editorials without original data, or were non-English without a translated abstract.

Two independent reviewers screened titles, abstracts, and full texts against the eligibility criteria; disagreements were resolved by consensus. Eligible studies (n = 38) were categorized into six intervention domains, and data were extracted on study design, sample size, intervention type, duration, and reported remission rates. Study quality was assessed using the Cochrane Risk of Bias Tool (RoB 2.0) for randomized trials and the Newcastle-Ottawa Scale for observational studies, and graded using a

GRADE-informed framework. Owing to substantial heterogeneity across studies, meta-analysis was not performed; a narrative synthesis was undertaken instead.



Figure 1: PRISMA 2020 flow diagram of study identification, screening, and inclusion (n = 38 studies in the final qualitative synthesis)

RESULTS AND DISCUSSION

Pathophysiological Basis: The Twin Cycle Hypothesis

An understanding of the pathophysiological substrate on which remission operates is essential before evaluating therapeutic interventions. The prevailing mechanistic framework for T2DM reversibility is the Twin Cycle Hypothesis, proposed by Taylor and colleagues, which posits that excess caloric intake drives progressive accumulation of ectopic fat in two key metabolic organs: the liver and the pancreas[8]. In the hepatic cycle, surplus dietary energy drives de novo lipogenesis, producing abnormal triglyceride deposition within hepatocytes; this hepatic steatosis impairs the ability of insulin to suppress hepatic glucose production, driving fasting hyperglycemia. Elevated hepatic VLDL triglyceride export subsequently delivers excess lipid to the pancreas, initiating the pancreatic cycle, which is directly toxic to beta-cell function and establishes the postprandial hyperglycemia characteristic of overt T2DM.

The critical therapeutic implication of this model is that both cycles are potentially reversible: sustained caloric restriction sufficient to deplete ectopic fat stores can restore insulin sensitivity and recover beta-cell responsiveness, particularly in patients with shorter disease duration and preserved beta-cell reserve[8,10]. Evidence for remission is most robust in patients with T2DM of fewer than six years' duration and residual beta-cell secretory capacity, as assessed by fasting or stimulated C-peptide levels.



Figure 2: The Twin Cycle Hypothesis - pathophysiological basis of T2DM and its reversibility

Dietary Modification and Caloric Restriction

Dietary interventions consistently produced rapid, clinically meaningful improvements in glycemic control, including complete T2DM remission without pharmacotherapy in selected individuals[6,11,12]. Structured very-low-calorie programs, most notably the DiRECT protocol, achieved remission in approximately 46% of participants at 12 months and 36% at 24 months[8], through hepatic fat clearance occurring within days of caloric restriction. Low-carbohydrate and ketogenic approaches have produced HbA1c reductions of 1.0-1.5%, with some studies reporting insulin discontinuation[13,14,15]. Fasting-mimicking dietary protocols have shown restoration of insulin secretion through beta-cell regeneration pathways involving neurogenin-3 (Ngn3)[11].

Weight Management and Physical Activity

Exercise-based interventions consistently produced HbA1c reductions of 0.5-1.5%, improved insulin sensitivity, and sustainable weight reduction[16,17], with combined aerobic and resistance training superior to either modality alone[17]. Sustained reductions of 10-15% of initial body weight are associated with the largest improvements in insulin sensitivity and beta-cell function[8,12], and remission rates are demonstrably higher with shorter disease duration and better-preserved beta-cell reserve.

Bariatric Surgery

Bariatric surgery provides the strongest and most durable evidence for T2DM remission. Roux-en-Y gastric bypass and sleeve gastrectomy consistently achieve HbA1c normalization below 6.5% and sustained weight loss exceeding 25-30% within 12 months[18,19,20], with long-term remission rates of 30-60% at five to ten years. Glycemic improvement frequently precedes weight loss, implicating weight-independent mechanisms including rapid changes in incretin hormone secretion, altered bile acid metabolism, and gut microbiota remodeling[19,20].

Pharmacotherapy: SGLT2 Inhibitors and GLP-1 Receptor Agonists

SGLT2 inhibitors reduce hyperglycemia via renal glycosuria and provide robust cardiorenal protection, including reductions in cardiovascular mortality, heart failure hospitalization, and hyperkalemia risk[21,22]. GLP-1 receptor agonists enhance glucose-dependent insulin secretion and promote weight loss with minimal hypoglycemia risk; combined therapy shows synergistic metabolic and cardiovascular benefit[23], representing the most pharmacologically sophisticated approach currently available for remission-supportive therapy, though neither class reliably produces complete remission in isolation.

Intermittent Fasting and Time-Restricted Feeding

Intermittent fasting protocols, including alternate-day fasting and time-restricted feeding, have emerged as accessible interventions capable of improving insulin sensitivity. Case series have demonstrated insulin discontinuation and glycemic normalization without hypoglycemic episodes[6], though optimal protocols and precise molecular mechanisms remain under investigation[24].

Stem Cell Therapy and Regenerative Medicine

Autologous bone-marrow-derived stem cell transplantation has produced improved glycemic control and temporary insulin independence in small-scale studies without major adverse events[25,26]. Human embryonic stem cells possess pluripotency and self-renewal capacity, enabling directed differentiation into pancreatic beta-like cells (Figure 3), though immune encapsulation, long-term viability, and scalable clinical translation remain unresolved challenges[3,26].



Figure 3: Generation of human embryonic stem cells (hESCs) for potential diabetes cell-replacement therapy

Gene Therapy and CRISPR-Based Innovations

Adeno-associated viral (AAV) vectors offer efficient, relatively low-immunogenicity delivery of gene therapy constructs, though beta-cell tropism and transduction efficiency remain technical challenges[27,28]. CRISPR-Cas9 gene-editing technology enables precise, targeted manipulation of genes involved in insulin signaling and beta-cell development; in experimental models, CRISPR-mediated modification of beta-cell transcriptional

regulators, including PDX1, MAFA, and PAX6, has improved insulin secretion and glucose homeostasis[29]. Genetic risk profiling is emerging as a preventive strategy, enabling early, targeted behavioral intervention in individuals with high-risk polygenic scores[27,30].

Strength of Evidence

Overall evidence quality varied substantially across intervention domains, as summarized in Table 1. Bariatric surgery and pharmacotherapy studies showed low-to-moderate risk of bias, supported by standardized outcome definitions and longitudinal follow-up. Lifestyle and weight-management studies showed moderate risk of bias, attributable to heterogeneity in adherence and self-reporting. Stem cell and gene therapy studies carried high risk of bias, reflecting small sample sizes and experimental designs; findings from these advanced modalities should be interpreted as hypothesis-generating.

TABLE 1: STRENGTH OF EVIDENCE - GRADE-INFORMED SUMMARY

Intervention	Key Outcomes	Risk of Bias	GRADE
Dietary Modification / Caloric Restriction	HbA1c reduction; hepatic fat clearance; complete remission in early T2DM	Moderate	Moderate
Physical Activity / Weight Management	1-2% HbA1c reduction; improved insulin sensitivity	Moderate	Moderate
Bariatric Surgery	HbA1c normalization (<6.5%); >25% weight loss; remission at 5 years	Low to moderate	High
SGLT2 Inhibitors	Glycemic control; weight loss; cardiorenal protection	Low	High
GLP-1 Receptor Agonists	Insulin release; weight reduction; minimal hypoglycemia	Low	High
Intermittent Fasting / TRF	Insulin discontinuation; metabolic flexibility	Moderate to high	Low
Stem Cell Therapy	Partial insulin independence; beta-cell regeneration	High (small samples)	Very low
Gene Therapy / CRISPR-Cas9	Experimental glycemic improvement	High (experimental)	Very low

Toward a Precision-Medicine Framework

The convergence of evidence across intervention types on a common endpoint - depletion of ectopic fat, restored hepatic insulin sensitivity, and recovered beta-cell function - suggests that beta-cells in early-to-moderate T2DM are suppressed rather than irreversibly destroyed[8]. Bariatric surgery currently occupies the apex of the evidence hierarchy, with robust data demonstrating durable normoglycemia at five to ten years in patients with severe obesity[18,19,20]. For clinicians managing patients with BMI ≥35 kg/m² and inadequately controlled T2DM, early referral for metabolic bariatric surgery should be considered disease-modifying rather than a last resort. Intensive lifestyle modification remains the most accessible pathway for the broader population, though adherence and behavioral support infrastructure remain the central barriers to population-level impact[8].

A dimension frequently underappreciated in remission discussions is the hypothalamic-pituitary-adrenal (HPA) axis (Figure 4). Chronic psychological stress drives sustained cortisol hypersecretion, which antagonizes insulin action, promotes visceral adiposity, and impairs beta-cell function[31], underscoring that remission cannot be achieved through dietary and pharmacological

intervention alone in patients experiencing chronic psychosocial stress. While evidence for regenerative and genetic modalities remains very low, CRISPR-Cas9 offers the theoretical possibility of a one-time, curative intervention in genetically defined diabetes subtypes; the primary remaining challenges are translational specificity and long-term safety rather than conceptual feasibility[26,28].



Figure 4: The hypothalamic-pituitary-adrenal (HPA) axis and its role in opposing T2DM remission

The synthesis presented here argues for a precision-medicine framework in place of a one-size-fits-all approach: patient phenotyping, encompassing disease duration, residual beta-cell function, degree of ectopic adiposity, polygenic risk, and psychosocial context, should guide selection and sequencing of remission-oriented interventions. Patients with short disease duration, elevated C-peptide, and significant obesity represent the highest-probability remission candidates for lifestyle intervention or bariatric surgery; those with longer disease duration may benefit most from combination pharmacotherapy as a bridge to lifestyle modification.

This review has limitations. The included literature is heterogeneous in design, protocol, and outcome definition, precluding meta-analysis. 'Remission' was not applied uniformly across primary studies, and most long-term remission data derive from high-income settings, limiting generalizability. The evidence base for regenerative and genetic interventions remains predominantly preclinical. This review was not prospectively registered (e.g., with PROSPERO), and inter-rater agreement during screening was not statistically quantified - both should be addressed in future updates.

CONCLUSION

Type 2 Diabetes Mellitus is not the inexorably progressive condition it was long assumed to be, but a metabolically reversible disease whose trajectory can be substantially altered, and in many patients reversed, through targeted, mechanism-based intervention. The Twin Cycle of hepatic and pancreatic ectopic fat accumulation is the central, remediable driver of T2DM, and its disruption through dietary modification, sustained weight loss, or bariatric surgery currently provides the

most robust pathway to durable remission. Newer pharmacological agents have expanded the clinician's toolkit through metabolic and cardiorenal benefit that synergizes with lifestyle-based strategies, while stem-cell-derived beta-cell therapies and CRISPR-mediated gene editing offer longer-term prospects contingent on overcoming translational barriers. Early intervention, sustained weight reduction, multidisciplinary support, and personalized matching of intervention to patient phenotype are the critical determinants of remission success.

ACKNOWLEDGMENT

The authors declare that this work received no external funding. The authors would like to thank the management of SBNM College of Pharmacy for providing the necessary facilities and support during the preparation of this manuscript.

CONFLICT OF INTEREST

No conflict of interest.

REFERENCES

1. ICMR. Indian Council of Medical Research Guidelines for Management of Type 2 Diabetes 2018. New Delhi: ICMR; 2018.
2. Zheng Y, Ley SH and Hu FB: Global aetiology and epidemiology of type 2 diabetes mellitus and its complications, Nature Reviews Endocrinology (2018), 14(2):88-98.
3. Kahn SE, Cooper ME and Del Prato S: Pathophysiology and treatment of type 2 diabetes: past, present, future, Lancet (2014), 383(9922):1068-1083.
4. Fowler MJ: Microvascular and macrovascular complications of diabetes, Clinical Diabetes (2008), 26(2):77-82.
5. Morrish NJ, Wang SL, Stevens LK, Fuller JH and Keen H: Mortality in the WHO Multinational Study of Vascular Disease in Diabetes, Diabetologia (2001), 44(Suppl 2):S14-S21.
6. Dixit JV, Badgujar SY and Giri PA: Reduction in HbA1c through lifestyle modification in newly diagnosed type 2 diabetes mellitus patients, Journal of Family Medicine and Primary Care (2022), 11(6):3312-3317.
7. Thrasher J: Pharmacologic management of type 2 diabetes mellitus: available therapies, American Journal of Medicine (2017), 130(6S):S4-S17.
8. Taylor R, Al-Mrabeh A and Sattar N: Understanding the reversibility of Type 2 Diabetes, Lancet Diabetes & Endocrinology (2019), 7(3):185-195.
9. American Diabetes Association: Standards of Medical Care in Diabetes-2023, Diabetes Care (2023), 46(Suppl 1):S1-S2.
10. Lim EL, Hollingsworth KG, Aribisala BS, Chen MJ, Mathers JC and Taylor R: Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol, Diabetologia (2011), 54:2506-2514.
11. Cheng CW, Villani V, Buono R, Wei M, Kumar S, Yilmaz OH, et al: Fasting-mimicking diet promotes Ngn3-driven beta-cell regeneration to reverse diabetes, Cell (2017), 168(5):775-788.
12. Divakaran S and Sasidharan PK: Diet and lifestyle to prevent, control or reverse type 2 diabetes, Annals of Clinical and Medical Research (2020), 1(3):1013.
13. Yancy WS Jr, Foy M, Chalecki AM, Vernon MC and Westman EC: A low-carbohydrate, ketogenic diet to treat type 2 diabetes, Nutrition & Metabolism (2005), 2:34.
14. Wheatley SD, Deakin TA, Arjomandkhah NC, Hollinrake PB and Reeves TE: Low Carbohydrate Dietary Approaches for People With Type 2 Diabetes, Frontiers in Nutrition (2021), 8:687658.
15. Merrill JD, Soliman D, Kumar N, Lynch A, Shukla N and Vidmar AP: Low-Carbohydrate and Very-Low-Carbohydrate Diets in Patients With Diabetes, Diabetes Spectrum (2020), 33(2):133-142.
16. Syeda UA, Battillo D, Visaria A and Malin SK: The importance of exercise for glycemic

control in type 2 diabetes, American Journal of Medicine Open (2023), 9:100031.
17. Kanaley JA, Colberg SR, Corcoran MH, Malin SK, Rodriguez NR, Crespo CJ, et al: Exercise/Physical Activity in Individuals with Type 2 Diabetes: ACSM Consensus Statement, Medicine & Science in Sports & Exercise (2022), 54(2):353-368.
18. Chumakova-Orin M, Vanetta C, Moris DP and Guerron AD: Diabetes remission after bariatric surgery, World Journal of Diabetes (2021), 12(7):1093-1101.
19. Haluzik M: Bariatric surgery and the mechanism of diabetes remission, Journal of Clinical Endocrinology & Metabolism (2013), 98(11):4336-4338.
20. Mingrone G, Panunzi S, De Gaetano A, Guidone C, Iaconelli A, Leccesi L, et al: Bariatric surgery versus medical therapy for type 2 diabetes, New England Journal of Medicine (2012), 366(17):1577-1585.
21. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al: Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes, New England Journal of Medicine (2015), 373(22):2117-2128.
22. Fu EL, Wexler DJ, Cromer SJ, et al: SGLT-2 inhibitors, GLP-1 RA, and risk of hyperkalemia in type 2 diabetes, BMJ (2024), 385:e078483.
23. Ryder REJ and DeFronzo RA: Diabetes medications with cardiovascular protection: can SGLT2i and GLP-1 RA complement each other?, British Journal of Diabetes (2020), 20(1):5-8.
24. Patterson RE and Sears DD: Metabolic effects of intermittent fasting, Annual Review of Nutrition (2017), 37:371-393.
25. Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al: Management of hyperglycemia in type 2 diabetes, 2018, Diabetes Care (2018), 41(2):266-282.
26. Buse JB, Wexler DJ, Tsapas A, Rossing P, Mingrone G, Mathieu C, et al: 2016 Standards of Medical Care in Diabetes, Diabetes Care (2016), 39(Suppl 1):S1-S112.
27. Cole JB and Florez JC: Genetics of diabetes and diabetes complications, Nature Reviews Nephrology (2020), 16(7):377-390.
28. Doudna JA and Charpentier E: Genome editing: the new frontier of genome engineering with CRISPR-Cas9, Science (2014), 346(6213):1258096.
29. Khan SH: The Promise of CRISPR Gene Therapy in Type-2 Diabetes Mellitus, Journal of Obesity Management (2019), 1(3):1-5.
30. Hallberg SJ, Gershuni VM, Hazbun TL and Athinarayanan SJ: Reversing Type 2 Diabetes: A Narrative Review of the Evidence, Nutrients (2019), 11(4):766.
31. Joseph JJ and Golden SH: Cortisol dysregulation: the bidirectional link between stress and type 2 diabetes, Annals of the New York Academy of Sciences (2017), 1391(1):20-34.

HOW TO CITE: Sohel Tamboli, Madhura Mundhe, Suraj Nanaware, Therapeutic Approaches to Type 2 Diabetes Remission: Challenges, Lifestyle Modifications, and Genetic Innovations, Int. J. of Pharm. Sci., 2026, Vol 4, Issue 8, 2304-2312. https://doi.org/10.5281/zenodo.21927152